81_FR_86209 81 FR 85980 - Meeting of the Chronic Fatigue Syndrome Advisory Committee

81 FR 85980 - Meeting of the Chronic Fatigue Syndrome Advisory Committee

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Federal Register Volume 81, Issue 229 (November 29, 2016)

Page Range85980-85980
FR Document2016-28723

As required by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that a meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will take place. This meeting will be open to the public.

Federal Register, Volume 81 Issue 229 (Tuesday, November 29, 2016) 
[Federal Register Volume 81, Number 229 (Tuesday, November 29, 2016)]
[Notices]
[Page 85980]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-28723]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Chronic Fatigue Syndrome Advisory Committee

AGENCY: Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Office of the Secretary.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As required by the Federal Advisory Committee Act, the U.S. 
Department of Health and Human Services is hereby giving notice that a 
meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will 
take place. This meeting will be open to the public.

DATES: Thursday, January 12, 2017, from 12:00 p.m. to 5:00 p.m. ET, and 
Friday, January 13, 2017, from 9:00 a.m. to 5:00 p.m. ET.

ADDRESSES: Individuals may attend this meeting in person and/or by 
utilizing virtual technology. Information for in-person attendance will 
be posted on the CFSAC Web site, http://www.hhs.gov/ash/advisory-committees/cfsac/meetings/index.html. Registration is required for in-
person attendance. Information on the procedure to follow for 
registration will be included on the CFSAC Web site. For individuals 
wishing to attend the meeting virtually, a webinar will be offered. 
Information about accessing the webinar will be included on the CFSAC 
Web site.

FOR FURTHER INFORMATION CONTACT: Gustavo Seinos, MPH, Designated 
Federal Officer, Chronic Fatigue Syndrome Advisory Committee, 
Department of Health and Human Services, 200 Independence Avenue SW., 
Room 712E, Washington, DC 20201. Please direct all inquiries to 
[email protected].

SUPPLEMENTARY INFORMATION: The CFSAC is authorized under 42 U.S.C. 
217a, Section 222 of the Public Health Service Act, as amended. The 
purpose of the CFSAC is to provide advice and recommendations to the 
Secretary of Health and Human Services, through the Assistant Secretary 
for Health on topics related to myalgic encephalomyelitis/chronic 
fatigue syndrome (ME/CFS). The issues can include factors affecting 
access and care for persons with ME/CFS; the science and definition of 
ME/CFS; and broader public health, clinical, research, and educational 
issues related to ME/CFS.
    The agenda for this meeting, call-in information, and location will 
be posted on the CFSAC Web site http://www.hhs.gov/ash/advisory-committees/cfsac/meetings/index.html.
    Thirty minutes will be allotted for public comment via telephone or 
in person on each day of the meeting. Each individual will have three 
minutes to present their comments. Priority will be given to 
individuals who have not provided public comment within the previous 
year. We are unable to place international calls for public comments. 
Individuals are required to register to participate in the public 
comment sessions. To request a time slot for public comment, please 
send an email to [email protected] by January 5, 2017. The email should 
contain the speaker's name and the telephone number at which the 
speaker can be reached for the public comment session.
    Individuals who would like for their testimony to be provided to 
the Committee members should submit a copy of the testimony prior to 
the meeting. It is preferred, but not required, that the submitted 
testimony be prepared in digital format and typed using a 12-pitch 
font. Copies of the written comment must not exceed 5 single-space 
pages, and it is preferred, but not required that the document be 
prepared in the MS Word format. Please note that PDF files, charts, and 
photographs cannot be accepted. Materials submitted should not include 
sensitive personal information, such as Social Security number, 
birthdate, driver's license number, passport number, financial account 
number, or credit or debit card number. If you wish to remain 
anonymous, then document must specify this.
    The Committee welcomes input on any topic related to ME/CFS.

Gustavo Seinos,
 Designated Federal Officer, CDR, USPHS.
[FR Doc. 2016-28723 Filed 11-28-16; 8:45 am]
 BILLING CODE 4150-42-P

85980 Federal Register / Vol. 81, No. 229 / Tuesday, November 29, 2016 / Notices Shepherd at least 7 days in advance of SUPPLEMENTARY INFORMATION: The DEPARTMENT OF HEALTH AND the meeting. CFSAC is authorized under 42 U.S.C. HUMAN SERVICES FDA is committed to the orderly 217a, Section 222 of the Public Health conduct of its advisory committee Service Act, as amended. The purpose National Institutes of Health meetings. Please visit our Web site at of the CFSAC is to provide advice and http://www.fda.gov/ recommendations to the Secretary of Government-Owned Inventions; AdvisoryCommittees/ Health and Human Services, through Availability for Licensing and AboutAdvisoryCommittees/ the Assistant Secretary for Health on Collaboration ucm111462.htm for procedures on topics related to myalgic AGENCY: National Institutes of Health, public conduct during advisory encephalomyelitis/chronic fatigue HHS. committee meetings. syndrome (ME/CFS). The issues can Notice of this meeting is given under ACTION: Notice. include factors affecting access and care the Federal Advisory Committee Act (5 for persons with ME/CFS; the science SUMMARY: The invention listed below is U.S.C. app. 2). and definition of ME/CFS; and broader owned by an agency of the U.S. Dated: November 22, 2016. public health, clinical, research, and Government and is available for Leslie Kux, educational issues related to ME/CFS. licensing and/or co-development to Associate Commissioner for Policy. The agenda for this meeting, call-in achieve expeditious commercialization [FR Doc. 2016–28605 Filed 11–28–16; 8:45 am] information, and location will be posted of results of federally-funded research BILLING CODE 4164–01–P on the CFSAC Web site http:// and development. Foreign patent www.hhs.gov/ash/advisory-committees/ applications are filed on selected cfsac/meetings/index.html. inventions to extend market coverage DEPARTMENT OF HEALTH AND Thirty minutes will be allotted for for companies and may also be available HUMAN SERVICES public comment via telephone or in for licensing and/or co-development. person on each day of the meeting. Each ADDRESSES: Invention Development and Meeting of the Chronic Fatigue individual will have three minutes to Marketing Unit, Technology Transfer Syndrome Advisory Committee present their comments. Priority will be Center, National Cancer Institute, 9609 AGENCY: Office of the Assistant given to individuals who have not Medical Center Drive, Mail Stop 9702, Secretary for Health, Department of provided public comment within the Rockville, MD 20850–9702. Health and Human Services, Office of previous year. We are unable to place FOR FURTHER INFORMATION CONTACT: the Secretary. international calls for public comments. Information on licensing and co- ACTION: Notice. Individuals are required to register to development research collaborations, participate in the public comment and copies of the U.S. patent SUMMARY: As required by the Federal sessions. To request a time slot for applications listed below may be Advisory Committee Act, the U.S. public comment, please send an email obtained by contacting: Attn. Invention Department of Health and Human to cfsac@hhs.gov by January 5, 2017. Development and Marketing Unit, Services is hereby giving notice that a The email should contain the speaker’s Technology Transfer Center, National meeting of the Chronic Fatigue name and the telephone number at Cancer Institute, 9609 Medical Center Syndrome Advisory Committee which the speaker can be reached for Drive, Mail Stop 9702, Rockville, MD (CFSAC) will take place. This meeting the public comment session. 20850–9702, Tel. 240–276–5515 or will be open to the public. Individuals who would like for their email ncitechtransfer@mail.nih.gov. A DATES: Thursday, January 12, 2017, from testimony to be provided to the signed Confidential Disclosure 12:00 p.m. to 5:00 p.m. ET, and Friday, Committee members should submit a Agreement may be required to receive January 13, 2017, from 9:00 a.m. to 5:00 copy of the testimony prior to the copies of the patent applications. p.m. ET. meeting. It is preferred, but not SUPPLEMENTARY INFORMATION: ADDRESSES: Individuals may attend this required, that the submitted testimony Technology description follows. meeting in person and/or by utilizing be prepared in digital format and typed Title of invention: Genetically virtual technology. Information for in- using a 12-pitch font. Copies of the Engineered Mouse-Derived Allograft for person attendance will be posted on the written comment must not exceed 5 Use in Preclinical Studies of Metastatic CFSAC Web site, http://www.hhs.gov/ single-space pages, and it is preferred, Melanoma Therapies. ash/advisory-committees/cfsac/ but not required that the document be Keywords: Melanoma, GDA, Allograft, meetings/index.html. Registration is prepared in the MS Word format. Please Genetically Engineered Mouse, required for in-person attendance. note that PDF files, charts, and immunological response. Information on the procedure to follow photographs cannot be accepted. Description of Technology: The for registration will be included on the Materials submitted should not include invention listed below is owned by an CFSAC Web site. For individuals sensitive personal information, such as agency of the U.S. Government and is wishing to attend the meeting virtually, Social Security number, birthdate, available for licensing and/or co- a webinar will be offered. Information driver’s license number, passport development in the U.S. in accordance about accessing the webinar will be number, financial account number, or with 35 U.S.C. 209 and 37 CFR part 404 included on the CFSAC Web site. credit or debit card number. If you wish to achieve expeditious commercialization of results of asabaliauskas on DSK3SPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: to remain anonymous, then document Gustavo Seinos, MPH, Designated must specify this. federally-funded research and Federal Officer, Chronic Fatigue The Committee welcomes input on development. Syndrome Advisory Committee, any topic related to ME/CFS. Before testing drugs in humans, drug Department of Health and Human developers are required to demonstrate Services, 200 Independence Avenue Gustavo Seinos, a reasonable expectation of safety and SW., Room 712E, Washington, DC Designated Federal Officer, CDR, USPHS. efficacy by performing so-called pre- 20201. Please direct all inquiries to [FR Doc. 2016–28723 Filed 11–28–16; 8:45 am] clinical studies. A key element of such cfsac@hhs.gov. BILLING CODE 4150–42–P trials is the use of animal models, VerDate Sep<11>2014 17:48 Nov 28, 2016 Jkt 241001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\29NON1.SGM 29NON1


Document Created: 2016-11-29 00:32:45
Document Modified: 2016-11-29 00:32:45
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesThursday, January 12, 2017, from 12:00 p.m. to 5:00 p.m. ET, and Friday, January 13, 2017, from 9:00 a.m. to 5:00 p.m. ET.
ContactGustavo Seinos, MPH, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee, Department of Health and Human Services, 200 Independence Avenue SW., Room 712E, Washington, DC 20201. Please direct all inquiries to [email protected]
FR Citation81 FR 85980 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR